Compare ABRDN Physical Gold Shares ETF (SGOL) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ABRDN Physical Gold Shares ETF vs 10X Genomics Inc — how do they compare? ABRDN Physical Gold Shares ETF trades at $39.86 (market cap $7.03B), while 10X Genomics Inc trades at $81.8 (market cap $10.07B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ABRDN Physical Gold Shares ETF for 57 Days and 10X Genomics Inc for 92 Days on average.
| SGOL | TXG | |
|---|---|---|
Market Cap | $7.03B | $10.07B |
Volume | 2,350,550 | 5,657,286 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $97.74 |
52-Week Low | $37.54 | $11.48 |
Typical Hold Time | 57 Days | 92 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOL trades at $39.81 with a 2.02% daily gain amid mixed technical signals. The overall technical picture remains bearish with moving averages indicating selling pressure, though oscillators show neutral momentum. Recent news highlights gold's sensitivity to Treasury yields and Federal Reserve policy expectations, with prices facing headwinds from rising rates but finding some support from inflation concerns and geopolitical tensions.
The outlook for SGOL is cautious with technical indicators favoring bearish momentum, while fundamental drivers depend on macroeconomic factors. Investment opportunities exist if inflation persists or geopolitical risks escalate, but risks include further rate hikes and dollar strength. Wall Street sentiment is divided with some analysts projecting declines to $4,100 while others see potential for $5,000 by mid-2027.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
